ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2023; 14(5):850-873. doi:10.7150/jca.81899 This issue Cite
Review
Recent Advancement of PD-L1 Detection Technologies and Clinical Applications in the Era of Precision Cancer Therapy
1. Binzhou Medical University, Yantai, Shandong, 264003, China
2. Binzhou People's Hospital Affiliated to Shandong First Medical University, Binzhou, Shandong, 256600, China
* These authors contributed equally.
Abstract
Programmed death-1 is a protein found on the surface of immune cells that can interact with its ligand, programmed death-ligand 1 (PD-L1), which is expressed on the plasma membrane, the surface of secreted cellular exosomes, in cell nuclei, or as a circulating soluble protein. This interaction can lead to immune escape in cancer patients. In clinical settings, PD-L1 plays an important role in tumor disease diagnosis, determining therapeutic effectiveness, and predicting patient prognosis. PD-L1 inhibitors are also essential components of tumor immunotherapy. Thus, the detection of PD-L1 levels is crucial, especially in the era of precision cancer therapy. In recent years, innovations have been made in traditional immunoassay methods and the development of new immunoassays for PD-L1 detection. This review aims to summarize recent research progress in tumor PD-L1 detection technology and highlight the clinical applications of PD-L1.
Keywords: programmed death-1, programmed death-ligand 1, immunoassay, immunosuppressant, tumor, precision cancer therapy.
Citation styles
